Raphael Pharmaceutical (RAPH) Liabilities and Shareholders Equity (2020 - 2025)
Raphael Pharmaceutical (RAPH) reported Liabilities and Shareholders Equity of $53000.0 for Q4 2025, up 96.3% on a YoY basis from $27000.0 in Q4 2024, and up 657.14% sequentially from $7000.0 in Q3 2025.
Raphael Pharmaceutical (RAPH) Liabilities and Shareholders Equity (2020 - 2025) Analysis & Trends
Raphael Pharmaceutical (RAPH) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $53000.0 in Q4 2025.
- For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 96.3% year-over-year to $53000.0; the trailing twelve-month figure through Dec 2025 stood at $183000.0 (down 67.26% YoY), and the FY2025 full-year result was $53000.0, up 96.3% from the prior year.
- Liabilities and Shareholders Equity improved to $53000.0 in Q4 2025, from $7000.0 in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $422000.0 in Q4 2021 to a low of $7000.0 in Q3 2025.
- A 5-year average of $164833.3 and a median of $124500.0 in 2022 frame the typical range for Liabilities and Shareholders Equity.
- Across the five-year window, Liabilities and Shareholders Equity surged 233.06% in 2023 and slumped 88.7% in 2024, its largest moves.
- Tracing RAPH's Liabilities and Shareholders Equity over 5 years: stood at $422000.0 in 2021, then fell by 21.09% to $333000.0 in 2022, then dropped by 28.23% to $239000.0 in 2023, then tumbled by 88.7% to $27000.0 in 2024, then jumped by 96.3% to $53000.0 in 2025.
- Business Quant data shows RAPH's Liabilities and Shareholders Equity at $53000.0 in Q4 2025, $7000.0 in Q3 2025, and $30000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 43.40 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 40.04 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 15.15 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 98.91 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 6.71 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 69.30 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 36.83 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 4.91 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.22 Bn |
| 10 | Raphael Pharmaceutical | 27.37 Mn | 27.33 Mn | - | 53,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 53,000.00 |
| Sep 30, 2025 | 7,000.00 |
| Jun 30, 2025 | 30,000.00 |
| Mar 31, 2025 | 93,000.00 |
| Dec 31, 2024 | 27,000.00 |
| Sep 30, 2024 | 51,000.00 |
| Jun 30, 2024 | 128,000.00 |
| Mar 31, 2024 | 353,000.00 |
| Dec 31, 2023 | 239,000.00 |
| Sep 30, 2023 | 403,000.00 |
| Jun 30, 2023 | 119,000.00 |
| Mar 31, 2023 | 150,000.00 |
| Dec 31, 2022 | 333,000.00 |
| Sep 30, 2022 | 121,000.00 |
| Jun 30, 2022 | 196,000.00 |
| Mar 31, 2022 | 180,000.00 |
| Dec 31, 2021 | 422,000.00 |
| Sep 30, 2021 | 62,000.00 |
| Dec 31, 2020 | 323,000.00 |